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Abstract
The criteria for differentiating symptomatic from asymptomatic HIV-associated neurocognitive 
disorder require evaluation of (1) cognitive impairment, (2) daily functioning declines, and (3) 
whether the functional declines are attributable to cognitive versus physical problems. Many 
providers rely only on self-report to evaluate these latter criteria. However, the accuracy of patient-
provided information may be limited. This study evaluated the validity of self-assessment for HIV-
associated neurocognitive disorder (HAND) diagnoses by comparing objective findings with self-
report of criteria 2 and 3 above. Self-reports were used to stratify 277 cognitively impaired HIV+ 
individuals into functionally dependent (n = 159) and independent (n = 118) groups, followed by 
group comparisons of objective functional problems. The dependent group was then divided into 
those who self-attributed their functional dependence to only cognitive (n = 80) versus only 
physical (n = 79) causes, for further comparisons on objective findings. The functionally 
dependent group was significantly worse than the independent group on all objective disability 
characteristics except severity of cognitive impairment, while those who attributed their 
dependence to physical (versus cognitive) factors were similar on all objective physical, cognitive, 
and functioning variables. Of note, 28 % of physical attributors showed no physical abnormalities 
on neuromedical examinations. Results suggest that patient report is consistently associated with 
objective measures of functional loss; in contrast, patient identification of physical versus 
cognitive causes is poorly associated with objective criteria. These findings caution against relying 
solely on patient self-report to determine whether functional disability in cognitively impaired 
HIV+ individuals can be attributed to strictly physical causes.
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Introduction
Neurocognitive impairment affects up to 50 % of HIV-infected (HIV+) individuals (Heaton 
et al. 2010). Those with cognitive impairments often have greater difficulties completing 
tasks that are important for daily functioning (e.g., driving, adhering to medication regimens; 
Heaton et al. 2004a; Hinkin et al. 2002; Marcotte et al. 1999), as well as have worse health 
outcomes (McCutchan et al. 2012), poorer insight into their functioning (e.g., Casaletto et al. 
2014), and a higher mortality rate (Tozzi et al. 2005) than comparable HIV+ individuals who 
are not cognitively impaired. Despite the increased risk of everyday difficulties, some HIV+ 
individuals with cognitive impairment remain functionally independent. This subgroup, 
classified as asymptomatic neurocognitive impairment (ANI), exhibits a profile of 
neurocognitive deficits identical to many of those with functional dependence (Heaton et al. 
2010). However, those with ANI depart from cognitively normal HIV+ individuals in that 
they evidence incident functional difficulties faster than their cognitively unimpaired HIV+ 
counterparts (Grant et al. 2014).
According to the current international “Frascati” classification criteria for HIV-associated 
neurocognitive disorder (HAND; Antinori et al. 2007), ANI is assigned when individuals 
exhibit at least mild cognitive impairment in two or more cognitive domains but whose 
everyday functioning difficulties either are not present or are present but unrelated to their 
cognitive impairments. In contrast, mild neurocognitive disorder (MND) is distinguished by 
at least mild cognitive impairment that is found to be associated with daily functioning 
difficulties (Antinori et al. 2007). Finally, HIV-associated dementia (HAD) is the most 
severe subcategory of HAND and is assigned when a patient has substantial cognitive 
impairment that is associated with more severe daily functioning difficulties (Antinori et al. 
2007). Therefore, the main diagnostic differentiations between the HAND subcategories 
involve assessing (1) the severity of cognitive impairment, (2) the presence and severity of 
daily functioning difficulties, and (3) if the individual’s functional difficulties can be 
attributed to their cognitive impairments. Differentiating these subcategories is helpful 
clinically both for determining how these impairments impact an individual’s daily life and 
for enhancing a clinician’s ability to predict the trajectory of a patient’s immediate needs. 
Therefore, the accuracy of current diagnostic practice warrants closer scrutiny.
Many clinicians and researchers rely on patient self-report to evaluate both the presence of 
functional dependence and whether this dependence can be attributed to their HIV-
associated cognitive deficits instead of strictly physical causes. Self-assessment of common 
everyday functioning declines has proven to be valid (e.g., Scott et al. 2011; Vigil et al. 
2008; Morgan et al. 2012). However, when the self-assessment relates to more complex 
concepts, such as general cognitive ability (e.g., “Am I unemployed for only physical 
reasons?” versus “Am I unemployed?”), inaccuracy is seen in up to 50 % of individuals with 
HIV (i.e., metacognitive deficit; Blackstone et al. 2012). In instances of meta-cognitive 
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deficits, self-reported neurocognitive difficulties are often related to affective distress rather 
than objective performances across cognitive domains (Hinkin et al. 1996; van Gorp et al. 
1991; Blackstone et al. 2012; Juengst et al. 2012). HIV-associated neurocognitive 
impairment increases the risk of these metacognitive disturbances (Casaletto et al. 2014; 
Juengst et al. 2012), even in cases of mild and asymptomatic neurocognitive impairment 
(Chiao et al. 2013). Of ecological relevance, such difficulties in awareness are linked to 
poorer everyday functioning outcomes among these individuals (Blackstone et al. 2012). 
While it is known that self-reported functional measures often relate to objective outcomes 
and cognitively impaired individuals are less accurate in assessing their own cognitive 
abilities, currently there is scant literature regarding patients’ abilities to accurately 
understand and differentiate the etiology (cognitive versus physical) of any daily functioning 
disabilities. Misclassification of HAND due to inadequate insight has important implications 
both on the patient (e.g., appropriate treatment/aids, prognostic recommendations) and 
public health concerns (e.g., driver’s license retention, HIV transmission risk behaviors).
The purpose of this study was to examine the validity of self-reported dependence in 
activities of daily living and of self-reported attribution of functional impairments (e.g., daily 
functioning dependence due to cognitive versus physical causes) in HIV+ individuals. In a 
large sample of cognitively impaired HIV+ adults, we evaluated the frequency and nature of 
reported functional dependence, the attribution of such dependence to cognitive versus 
physical causes, and the associations of these attributions to objective real-world, 
neuromedical, and cognitive findings. Affective distress could also be a cause of disability or 
functional decline (e.g., major depressive disorder) or instead could be a reaction to 
functional decline as disability (current depressive symptoms); therefore, depression and 
depressive symptoms also were evaluated. In comparisons between Activities of Daily 
Living (ADL) independent and dependent individuals, we hypothesized that the dependent 
group would demonstrate worse objective functional disability, physical problems, and 
possibly cognitive performance. Within the functionally dependent group, we evaluated the 
validity of self-reported etiology of functional dependence by comparing those who 
attributed their dependence to only physical problems and those who reported only cognitive 
contributions to their functioning dependence. If these self-reported attributions were 
accurate, we would expect the self-reported physical attribution group to have more physical 
problems identified in objective neuromedical examinations, but relatively better objective 
cognitive functioning than the cognitive attributors. The results of our study have significant 
implications concerning the weight clinicians can assign to patient self-report in the 
classification of symptomatic versus asymptomatic HAND.
Method
Participants
This study included 277 HIV-seropositive (HIV+) participants from the CNS Anti-Retroviral 
Therapy Effects Research (CHARTER) study cohort, which was funded by the National 
Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and 
Stroke (NINDS). CHARTER is a multi-site national study aimed at determining the 
prevalence and nature of HIV-related central nervous system complications in the era of 
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combination anti-retroviral therapy (cART). The study cohort included HIV+ adults at 
varying stages of disease and with different histories of antiretroviral medication use (ART).
Because the purpose of the current study was to examine the process of assigning HAND 
subcategories, all participants included in this sample were first required to be eligible for a 
HAND diagnosis. The diagnostic criteria for HAND (DSM-IV guidelines and Frascati 
criteria; Antinori et al. 2007) require the presence of at least mild impairment in at least two 
of the seven cognitive domains (see below for a list of domains included) using standardized 
guidelines for clinical ratings to classify the presence and severity of the neurocognitive 
impairment (see Woods et al. 2004). In line with the international Frascati criteria for 
categorizing subtypes of HAND, if participants in this study experienced a loss of functional 
independence in addition to their cognitive impairment, we required that to be included in 
the analyses regarding cognitive versus physical attribution they had to have attributed the 
dependence to either only cognitive or only physical causes. Potential participants were not 
included if they failed to provide a definitive judgment regarding physical versus cognitive 
causation. Additionally, HAND requires the impairment be primarily due to HIV, therefore 
those with significant confounding conditions that could better explain the cognitive 
impairment (e.g., stroke) were excluded from this study.
Participants completed the study assessments at one of six university centers: John Hopkins 
University (Baltimore, MD), Icahn School of Medicine at Mount Sinai (New York, NY), 
University of California at San Diego (San Diego, CA), University of Texas Medical Branch 
(Galveston, TX), University of Washington (Seattle, WA), and Washington University (St. 
Louis, MO).Study procedures were approved by the Human Subjects Protection Committees 
of each participating university. All participants provided written informed consent prior to 
study participation.
Materials and procedures
Participants completed a comprehensive neuromedical examination, neurocognitive test 
battery, self-report questionnaires, and a structured psychiatric interview (see below and 
Heaton et al. 2010 for further details).
Demographics
On average, participants were 44.0 (SD = 7.7) years old. The sample was 75 % male and 
48 % non-Hispanic white and completed an average of 12.7 (SD = 2.5) years of education.
Disease characteristics
All participants completed a standard medical examination. Blood and urine specimens were 
collected in order to evaluate disease status and recent substance use. HIV infection was 
diagnosed by the enzyme-linked immunosorbent assay (ELISA) followed by a Western blot 
test. Routine clinical chemistry panels, rapid plasma reagin, blood counts, hepatitis C virus 
(HCV) antibody, and CD4+ T cells (flow cytometry) were performed at each participating 
institution’s medical center laboratory. HIV RNA levels were measured in plasma and 
cerebrospinal fluid by reverse transcriptase-polymerase chain reaction (Roche Amplicor, v. 
1.5, lower limit of quantitation 50 copies/mL). Nadir CD4 and antiretroviral medication 
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(ART) regimen were collected during the medical history interview. Overall, 64 % of 
participants had a diagnosis of acquired immune deficiency syndrome (AIDS). The average 
nadir CD4 count was 186.6 (SD = 173.3).
Disability characteristics
Everyday functioning difficulties
Self-report assessment—Participants completed a modified version of the Lawton and 
Brody (1969) ADL scale (Heaton et al. 2004a, b; Woods et al. 2006). This ADL scale is a 
self-report questionnaire that rates participants’ current and best levels of independence on 
16 functional domains (i.e., employment, planning and initiating social activities, 
comprehension of reading/television, housekeeping, home repairs, financial management, 
general shopping, buying groceries, laundry, cooking, managing transportation, medication 
management, telephone use, child care, bathing, and dressing). The 16 items describe the 
extent to which participants independently function on both basic (e.g., bathing, dressing) 
and instrumental (e.g., managing finances, cooking, housekeeping) activities of daily living. 
The ADL total score represents the total number of domains for which there is a decline in 
an individual’s completion of the task on their own now compared to their best previous 
level of functioning (e.g., previously versus now “I am able to dress myself and pick out my 
own clothes,” “I dress myself, but someone else must pick out my clothes for me,” “I need 
occasional assistance getting dressed or frequently make mistakes in choosing clothes,” “I 
need frequent assistance in getting dressed”), with a total score ranging from 0 (no 
functional declines) to 16 (decline toward dependence in all activities). Declines on two or 
more of the 16 domains were used as a cutoff for overall functional dependence, consistent 
with the Frascati criteria for symptomatic HAND (Antinori et al. 2007; Heaton et al. 2004a, 
b).
Objective assessment—Employment status was determined by a single-item response 
on the Patient’s Assessment of Own Functioning Inventory (PAOFI; Chelune et al. 1986; 
“Are you presently holding a job?”).
Causal attribution of functional impairment
Self-report assessment—Participants were asked to report whether the everyday 
functioning dependence endorsed on the ADL scale was due to physical difficulties (n = 79; 
e.g., the participant cannot shop because their peripheral neuropathy precludes them from 
walking around the store) or cognitive problems (n = 80; e.g., the participant has difficulties 
shopping because it is too difficult to remember which grocery items are needed).
Objective assessment
Cognitive performance—Participants were administered a comprehensive 
neurocognitive test battery that included tests in the following seven cognitive domains: 
speed of information processing, learning, delayed recall, executive function, verbal fluency, 
attention/working memory, and complex motor skills. See Heaton et al. (2010) for battery 
details. Raw test scores were converted to normally distributed and demographically 
corrected standard scores (T scores adjusted for age, education, sex, and race/ethnicity 
Obermeit et al. Page 6
J Neurovirol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
where available) using the best available normative standards (Heaton et al. 2002, 2004b; 
Norman et al. 2011). T scores on each of the neurocognitive measures were converted into a 
deficit score using a five-point scale (Carey et al. 2005). The average of the deficit scores 
from each test generated a global deficit score (GDS) for each study participant, which 
reflects the number and severity of impairments across all measures (Carey et al. 2005). 
Neuropsychological impairment was defined as a GDS of ≥0.5, a cutoff that provides the 
best balance between sensitivity and specificity (e.g., Carey et al. 2005).
Physical disability—The Karnofsky Performance Status Scale (Karnofsky scale; 
Karnofsky and Burchenal 1949) was used to provide a neuromedical clinician rating of 
health-related functioning. During the neuromedical examination and collection of medical 
history, clinicians assessed multiple areas of physical difficulties that are often associated 
with HIV (e.g., neuropathy), as well as the impact of disease on daily functioning. The 
Karnofsky index ranges from 0 (indicating death) to 100 (indicating normal functioning/no 
complaints or signs of disease).
During the neuromedical examination, clinicians administered standard neurologic tests 
evaluating distal-to-proximal gradients of reflex elicitation and sensation as well as 
assessments of other areas of physical disabilities. A committee of experts extracted 11 
common HIV-associated physical outcomes from the medical examination to create a 
composite variable representing patients’ physical disability. These key variables included 
gait/balance disturbance, impaired hand coordination, involuntary movements (e.g., tremors, 
jerks), muscle weakness, myopathy, dysesthesias (e.g., burning, aching, shooting pain), 
parasthesias (e.g., tingling), loss of sensation, bladder control, weight loss, and diarrhea. 
Based on a participant’s performance or response on each area of function, clinicians 
assigned a severity rating from 0 (normal) to 4 (severe). Two composite scores were derived 
from the 11 physical disability variables. The Total Number of Abnormal Findings 
composite is a continuous variable that represents the number of physical disabilities that 
were rated at least moderately severe (≥2). The Sum of Severity Ratings composite is a 
continuous variable derived by summing raw scores from the 11 HIV-associated physical 
outcome variables to determine the overall severity of their physical disability.
Psychiatric interview
Current depressive symptoms were assessed with the Beck Depression Inventory II (BDI-II; 
Beck et al. 1996). The computer-assisted Composite International Diagnostic Interview 
(CIDI version 2.1 World Health Organization 1998) is a structured clinical interview that 
was used to diagnose current (last 30 days) and lifetime mood and substance use disorders 
using DSM-IV criteria.
Statistical analysis
To examine the validity of self-reported ADL dependence and causal attribution, two 
separate sets of group comparisons (functionally dependent versus functionally independent, 
and cognitive versus physical attributors) were completed utilizing chi-square and Student’s 
t tests (for normally distributed variables) or Wilcoxon Rank-Sum test (for non-normally 
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distributed variables; i.e., education, premorbid verbal IQ estimate, duration of HIV, nadir 
CD4, current CD4, plasma viral load, severity of cognitive impairment, total number of 
abnormal findings on the neuromedical exam, sum of severity ratings for abnormal 
neuromedical findings, and BDI-II). In each analysis, we evaluated the consistency between 
self-reported versus objective levels of functioning/disability within the same construct (e.g., 
physical attribution with medically documented physical disabilities). The first set of group 
comparisons (Table 1) identified differences between the self-reported functionally 
dependent and independent groups. To evaluate the validity of these self-reported 
differences, we examined whether there was worse objective functional dependence (e.g., 
higher rates of unemployment) and disability ratings by the neuromedical clinician in the 
self-reported dependent group than the self-reported independent group and whether other 
objective performance indicators were worse in the dependent group (i.e., cognitive and 
physical findings). The second set of comparisons (Table 2) evaluated differences between 
those who self-reported the attribution of their functional dependence to physical versus 
cognitive causes. Because attributions represent the causes of functional dependence, only 
those in the dependent group were included in the second set of group comparisons. To 
evaluate the validity of causal attribution, we examined whether those who attributed their 
functional dependence to cognitive causes had worse objective neurocognitive performance 
than those who attributed their dependence to strictly physical causes and whether physical 
attributors had worse physical disabilities on the objective neuromedical examinations 
compared to those who attributed dependence to strictly cognitive problems. Because 
psychiatric variables robustly predict self-report, the differences in psychiatric variables 
(current depressive symptoms, and both current and lifetime depression and substance use 
disorders) between the aforementioned groups were also evaluated.
Nature of disability in HIV infection
To understand which daily activities were identified as most problematic to participants, the 
prevalence of declines on each item of the ADL scale was compared across the above-
mentioned groups (i.e., functionally dependent versus functionally independent and 
cognitive versus physical attributors).
Results
Of the 277 non-confounded HIV+ individuals with cognitive impairment in the CHARTER 
multi-site US study, 159 (57 %) reported decreased independence in at least two ADLs 
surveyed by the modified Lawton and Brody Scale (i.e., “functionally dependent”). A 
significance alpha level of .05 was used for all analyses.
ADL-dependent versus ADL-independent group comparisons
Demographics and disease characteristics
Table 1 shows differences between those who were functionally dependent (n = 159) and 
independent (n = 118). Compared to those who reported ADL independence, the dependent 
participants were demographically similar (i.e., age, gender, ethnicity, education, and 
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reading-based estimate of premorbid intelligence) and had similar current HIV health and 
treatment status (p > .05).
Disability characteristics
Compared to those who reported ADL independence, dependent participants had a similar 
prevalence of current and lifetime substance use disorder, severity of cognitive impairment, 
and demographically corrected cognitive domain T scores (p > .05) but were significantly 
worse on all other disability variables including clinician-rated functional disability 
(Karnofsky), current depressive symptoms (BDI-II), higher prevalence of current and 
lifetime depression, higher rates of unemployment, and significantly worse findings on all 
objective physical examination variables (p < .05).
Nature of ADL declines in HIV infection
For dependent individuals, we next considered which ADLs they were most likely to need 
help with in their everyday lives (Fig. 1). Compared to the independent participants, the 
dependent participants showed higher frequencies of dependence on all 16 ADL items. The 
most frequently endorsed areas of difficulty were employment, planning and initiating social 
activities, housekeeping, and understanding TV programs and reading materials (all above 
40 % in the dependent group).
Cognitive versus physical attributions for ADL declines
Within the functionally dependent cohort (n = 159), Table 2 shows the differences between 
those who attributed their functional difficulties to cognitive (n = 80; 50 %) versus strictly 
physical (n = 79; 50 %) problems.
Demographics and disease characteristics
Compared to the participants with cognitive attribution of their functional disability, those 
with a strictly physical attribution were similar on most demographic and disease 
characteristics. However, the physical attribution group was slightly older (46.0 versus 42.9) 
and had significantly longer duration of HIV, lower nadir CD4, and higher rates of AIDS (p 
< .05).
Disability characteristics
Compared to the cognitive attribution group, the physical attributors did not differ on current 
major depressive disorder, current or lifetime substance use disorders, or any of the objective 
findings including everyday functioning (employment), severity of cognitive impairment, 
demographically corrected cognitive domain T scores, or physical problems on examination, 
or neuromedical clinician rating of functioning (Karnofsky; p > .05). Also, 28 % of physical 
attributors showed no physical abnormalities on examination. The only characteristics that 
did differ were that the cognitive attribution group reported a greater number of depressive 
symptoms and higher prevalence of lifetime major depressive disorder compared to the 
physical attribution group (p < .05).
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Nature of disability attribution in HIV infection
Of the 16 domains of daily functioning activities queried in the modified Lawton and Brody 
ADL form (Fig. 2), only two were reported as less problematic by participants who 
attributed their dependence to strictly physical causes (housekeeping and understanding 
reading and television material; p < .05). Although understanding reading and television 
materials has primarily cognitive requirements on face value, almost one third (29 %) of 
participants with strictly physical attributions reported needing help on this task and a 
relatively high percentage of participants who thought they had strictly physical disabilities 
reported needs for help with other cognitively demanding activities such as planning and 
initiating social activities (62 %) and financial management (13 %). No group differences 
were noted on the other 14 daily activity items.
Discussion
The purpose of this study was to determine whether, in cognitively impaired HIV+ 
individuals, self-reported dependence in daily functioning and self-reported causal 
attribution of this dependence are associated with relevant/ supporting objective variables 
and, as such, whether such self-reports are valid stand-alone tools for diagnosing 
“symptomatic” HAND subtypes. As hypothesized, reports of ADL dependence were 
consistently associated with objective evidence of worse disability and more impaired 
everyday functioning. Dependent participants did not have more severe cognitive 
performance (either at the domain level or when measured with a global cognitive score), 
which is consistent with prior findings that the HAND subtypes of “Asymptomatic 
Neurocognitive Impairment” (ANI) and “Mild Neurocognitive Disorder” (MND) have quite 
similar neurocognitive profiles, as noted above; however, ANI does confer a significantly 
increased risk for transitioning to symptomatic HAND over time (Grant et al. 2014). It was 
anticipated that, if attributions of the cause of ADL dependence were valid, participants with 
strictly physical causes would have worse objective neuromedical physical findings and 
those who indicated cognitive causes would show worse performance on neuropsychological 
testing. By and large, this is not what the data showed. Self-assessed cognitive attribution of 
functional dependence was consistently associated with other measures of psychiatric 
disabilities, but was not consistently associated with any objective measures [cognitive (both 
global and domain scores), neuromedical, or daily functioning]. Additionally, cognitive and 
physical attributors did not report consistent differences in their ability to complete tasks that 
were either more cognitively (e.g., manage finances or medications) or physically (e.g., 
home repairs, laundry, or bathing) demanding. In fact, the only specific daily functioning 
tasks that cognitive and physical attributors differed on were housekeeping and 
understanding television and reading materials. While understanding reading and television 
materials requires primarily cognitive skills, one third of physical attributors reported 
significant difficulties of this nature, and while housekeeping may be more physically than 
cognitively demanding, cognitive attributors reported significantly higher rates of difficulty 
on this task than physical attributors (51 versus 35 %). Relevant to potential insight 
problems, more than a quarter of physical attributors evidenced no current physical 
abnormalities on neuromedical examinations. Considered together, these results suggest that 
HIV+ individuals may be able to accurately assess the presence of functional dependence, 
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but struggle to make accurate assessments about the cause of their functional declines. 
Consistent with previous studies (e.g., Blackstone et al. 2012), our results indicate that self-
reported attribution (especially of cognitive-based difficulties) may be more closely related 
to affective distress than objective or real-world indicators of causation.
One possible factor contributing to limited accuracy in attribution of causation among 
functionally dependent HIV+ individuals may be poor metacognition. Metacognition 
involves the conscious knowledge and monitoring of one’s own cognitive processes (Toglia 
and Kirk 2000) and is commonly conceptualized as part of “executive functioning” 
processes that involve the medial prefrontal brain systems (e.g., Brodmann’s area 10, 
Johnson et al. 2006; Stuss 2011). Prior literature suggests that up to 50 % of HIV+ 
individuals evidence a metacognitive deficit and that metacognitive inaccuracies are 
associated with poorer neurocognitive functioning (e.g., Hinkin et al. 1996; Casaletto et al. 
2014) and worse self-reported predictions of cognitive performance (Casaletto et al. 2014). 
These metacognitive deficits extend beyond the HIV+ population. Individuals with non-
HIV-associated neurodevelopmental disorders (e.g., attention-deficit/hyperactivity disorder) 
evidence similar difficulties in self-assessing their disabilities (e.g., driving safety self-report 
compared to actual performance; Knouse et al. 2005). In fact, in other populations known to 
have reduced cognitive (e.g., traumatic brain injury) and specifically executive function (e.g., 
schizophrenia) abilities, not only is poor metacognition observed (Hart et al. 1998; O’Keeffe 
et al. 2007; Gould et al. 2015), but metacognitive impairments are predictive of real-world 
functioning above and beyond cognitive and functional capacity testing (Gould et al. 2015). 
Given the complex metacognitive abstraction required in order to accurately identify the 
nature and, especially, etiology of functional problems and the prefrontal neural and 
cognitive systems often impacted by HIV infection, it may not be surprising that HIV+ 
participants evidenced difficulties with such granular self-reflective questions. While these 
studies provide a framework for understanding poor self-assessment in HIV, future studies 
should evaluate the direct link between metacognitive deficits and self-reported causal 
attribution inaccuracies to confirm this possible mechanistic explanation of poor attributional 
self-report.
Additionally, it is likely that affective distress may also contribute to these self-report 
discrepancies. Depression often occurs in the context of HIV infection (Catz et al. 2002; 
Kelly et al. 1993) and is associated with more rapid HIV disease progression, higher rates of 
mortality (Ickovics et al. 2001), and worse everyday functioning difficulties (e.g., 
Ammassari et al. 2004). In fact, ADL-dependent individuals reported very high rates of 
depressive symptoms on the BDI-II and almost a quarter of them met criteria for current 
major depressive disorder (Table 1). While everyday functioning difficulties are elevated in 
depressed individuals, the subjective perception of both physical disability severity 
(Severeijns et al. 2001) and cognitive deficits (Farrin et al. 2003) can also be significantly 
influenced by psychological distress. Across the literature, poor mood is a robust predictor 
of self-reported quality of life (e.g., Pompili et al. 2013), as well as less accurate self-
awareness (e.g., Juengst et al. 2012), and increased complaints of cognitive difficulties (e.g., 
van Gorp et al. 1991). Therefore, it is no surprise that our results showed that self-reported 
cognitive attribution was primarily associated with current mood and lifetime depression, but 
not with objective measures of physical and cognitive impairments. Blackstone et al. (2012) 
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identified that current mood influenced self-reports of daily functioning in HIV+ participants 
and, when relying solely on self-report to diagnose HAND, a greater number of patients 
were categorized as having HAD than when using more objective assessments. Further, by 
augmenting self-report assessment by also including performance-based evaluation of 
functioning, this depression bias was reduced and the specificity of differentiating 
asymptomatic versus symptomatic HAND improved (Blackstone et al. 2012).
Limitations
While the present study provides insight into the validity of self-report measures for 
differential diagnosis of HAND subtypes, some limitations exist. Some of the objective 
measures used here were at least partly influenced by participant responses. For example, 
while the Karnofsky scale represents a clinician’s rating of the patient’s performance on a 
physical examination, clinicians use information gathered from the patient during the 
medical history to inform their assessment. Additionally, there were no direct evaluations of 
the functional domains on which patients reported dependence (e.g., using the telephone). 
Although employment was used as one representation of objective everyday functioning 
performance, we recognize that employment may be influenced by factors outside of 
everyday functioning abilities (e.g., availability of jobs, qualifications for available jobs, 
motivation to obtain employment) and therefore is an imperfect representation of objective 
daily functioning. Furthermore, this study only captured the dichotomous response of 
whether participants were or were not employed. However, the level of occupational 
functioning in their current position as well as whether their occupational responsibilities, 
type of work, pay, or full-time status were decreased as a result of functional decline were 
not evaluated among those employed. Future studies would benefit from more refined real-
world functional assessment. Despite the alternative explanations for unemployment and 
possible functional declines for those who retained employment, unemployment is 
consistently a robust predictor of other everyday functioning measures throughout the 
literature (e.g., Kalechstein et al. 2003; Heaton et al. 2004a, b) and likely provides a 
reasonably adequate proxy for more detailed employment information for the purposes of 
the current study. While a panel of experts in the neurological effects of HIV designed the 
physical composite variable, its psychometric properties remain unknown as this is the first 
study to use the composite. Finally, the cross-sectional nature of this sample precludes us 
from evaluating the change in attribution over time. It is possible that over time patients’ 
objective findings and subjective reports may become more convergent as their disease 
progresses and their cognitive versus physical declines become more apparent.
Clinical implications
These findings have significant implications for the weight we assign to a patient’s own 
attribution of everyday functioning dependence. Especially when these determinations guide 
our diagnostic categorizations, as in HAND, accuracy of the causative attribution of reduced 
functioning is important. A misdiagnosis of asymptomatic HAND could result in delayed 
interventions (e.g., a patient may not be provided with oversight of or cognitive tools for 
improving medication management because the cause of mismanagement is not attributed to 
forgetfulness), more rapid disease progression (e.g., if medications are mismanaged by the 
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patient, viral suppression may be lost), imprecise clinical recommendations (e.g., patients, 
family members, and clinicians may not monitor a patient’s needs/concerns as closely if the 
patient is deemed functionally intact regarding cognitive abilities), and an increased risk of 
public health concerns (e.g., driving privileges may continue unchecked despite decreased 
driving ability due to impaired cognition). To enhance the accuracy of attributions, clinicians 
may be able to add short everyday functioning measures (e.g., UCSD Performance-Based 
Skills Test, which takes less than 10 min to complete; Mausbach et al. 2008) to evaluate the 
cognitive capacity associated with everyday functioning tasks, screen for depressive 
symptoms to be more alert to possible affective bias, possibly refer participants for more 
thorough neuropsychological testing and/ or neuromedical assessments, and maybe even 
obtain corroborating information from observers in order to differentiate the cognitive versus 
physical causes of known functional decline with more objective information. In instances 
where self-report of attribution does not correspond with objective performance/information, 
clinical judgment may help weigh the objective evidence more than subjective self-report to 
provide a more accurate differential diagnosis for HAND. In any event, whenever there is 
clear evidence of significant cognitive impairment, one should be wary about attaching the 
“asymptomatic” label based only upon self-report of non-cognitive attribution of causes of 
dependence.
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Fig. 1. 
Frequency of items endorsed by the functionally dependent and independent groups. Note. 
All items significantly differed (p < .001) between dependent and independent groups
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Fig. 2. 
Frequency of functional dependence items endorsed by cognitive and physical attributors in 
the dependent group. Note. Double asterisks indicate significant differences in frequency of 
endorsement between the two attribution groups at the significance level of p < .01; single 
asterisk indicates a significance level of p < .05
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